Remdesivir was approved for emergency use in the treatment of COVID-19 by various health authorities, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and others. The decision to use Remdesivir in COVID-19 patients is based on clinical trials and data available at that time, which suggested that the drug might be beneficial in reducing the severity and duration of illness in some patients.
Regarding your statement about Remdesivir causing deaths in an Ebola trial, there seems to be a misunderstanding. Remdesivir was not associated with causing deaths in a trial for Ebola. Remdesivir was actually studied as a potential treatment for Ebola virus disease, but the trials did not show significant benefits in improving survival rates for Ebola patients. However, it is important to note that the reasons for the lack of efficacy in Ebola may not directly translate to its use in COVID-19, as these are different viruses with distinct characteristics and mechanisms of infection.
Medical treatments and interventions are continually evaluated through clinical trials and real-world data to ensure their safety and efficacy. Decisions on drug usage are made based on the best available evidence and are subject to updates as new information becomes available.
It's essential to remember that medicine is a constantly evolving field, and recommendations can change based on the latest scientific findings and clinical experience. Therefore, if you have any questions or concerns about specific treatments for COVID-19 or any other medical condition, it is best to consult with qualified healthcare professionals who have access to the most up-to-date information and can provide personalized advice based on your individual health situation.